The Mass Balance Study of LP-168 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

February 2, 2024

Study Completion Date

March 13, 2024

Conditions

Clinical Pharmacology

Interventions

DRUG

[14C]LP-168

single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state

Trial Locations (1)

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

Guangzhou Lupeng Pharmaceutical Company LTD.

INDUSTRY

NCT06126861 - The Mass Balance Study of LP-168 in Healthy Subjects | Biotech Hunter | Biotech Hunter